Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP1848 (Glepaglutide) in Short Bowel Syndrome
NCT02690025Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Started Feb 2016; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT02690025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690025.